JAZZ Maintained by Barclays -- Price Target Raised to $271

gurufocus.com · 2026-09-10

On October 26, 2023, Barclays maintained an Overweight rating on Jazz Pharmaceuticals (JAZZ). The price target was adjusted upwards from $270.00 to $271.00, ref

TickrTrends take: Barclays' price target increase to $271 occurs while TickrTrends rates Jazz Pharmaceuticals as fairly valued, suggesting the analyst projection sits above current market pricing but within a reasonable valuation range for the Healthcare sector company. A fairly valued rating typically indicates limited upside potential in the near term, so valuation-focused investors should monitor whether additional analyst upgrades or company fundamentals shift the consensus sufficiently to justify movement toward Barclays' target. The maintained rating alongside the raised price target reflects analyst confidence in the company's prospects while the market may already be pricing in much of that optimism.

Read the full story at gurufocus.com →